Lancet Diabetes Endocrinol

Continuous glucose monitoring in gestational diabetes: Does it make a difference?

June 2, 2025

Real-time continuous glucose monitoring wasn’t superior to standard self-monitoring for gestational diabetes, in this randomized trial. Perinatal outcomes such as neonatal hypoglycemia and large-for-gestational-age prevalence were similar between groups, as were maternal glycemic parameters. However, continuous monitoring was preferred by patients.

• Study details: This open-label trial randomized pregnant patients (N=302) ages 18–45 years with gestational diabetes to continuous vs. standard self-monitoring. Randomization factored in pre-pregnancy BMI, personal history of gestational diabetes, family history of type 2 DM, as well as ethnicity. Primary endpoint: perinatal outcomes composite: large for gestational age, macrosomia, neonatal hypoglycemia, polyhydramnios, stillbirth. Key secondary outcomes: patient preference, maternal glycemic control.
• Results: The perinatal composite outcome didn’t differ significantly between groups. Skin changes occurred in 4% of the continuous monitoring group vs. <1% of the standard monitoring group. Continuous monitoring was preferred by patients.

Source:

Amylidi-Mohr S, et al. (2025, May 26). Lancet Diabetes Endocrinol. Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial. https://pubmed.ncbi.nlm.nih.gov/40441173/